Drug intelligence / Profile preview

ICT01 + aldesleukin + pembrolizumab

Development stage: Unknown
Lead developer: Ipsen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

ICT01 + aldesleukin + pembrolizumab is an investigational combination therapy composed of three agents: ICT01, a monoclonal antibody targeting the immune receptor BTN3A expressed on immune and tumor cells; aldesleukin, a recombinant interleukin-2 (IL-2) acting as a cytokine therapy to stimulate T cell proliferation and activation; and pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor classified as an immune checkpoint inhibitor. This experimental combination is under clinical investigation for its potential synergistic immunostimulatory and antitumor effects, aiming to enhance T cell-mediated antitumor immunity in patients with advanced and/or refractory solid tumors.

Other names: IL-2IL2IL 2

Targets

BTN3A (Butyrophilin subfamily 3 member A)IL-2R (Interleukin-2/interleukin-15 receptor complex)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on ICT01 + aldesleukin + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICT01 + aldesleukin + pembrolizumab.

Explore the full profile